+

WO1998018486A1 - Utilisation de la leptine pour stimuler l'hematopoiese - Google Patents

Utilisation de la leptine pour stimuler l'hematopoiese Download PDF

Info

Publication number
WO1998018486A1
WO1998018486A1 PCT/US1997/018875 US9718875W WO9818486A1 WO 1998018486 A1 WO1998018486 A1 WO 1998018486A1 US 9718875 W US9718875 W US 9718875W WO 9818486 A1 WO9818486 A1 WO 9818486A1
Authority
WO
WIPO (PCT)
Prior art keywords
cells
hematopoietic
leptin
lin
kit
Prior art date
Application number
PCT/US1997/018875
Other languages
English (en)
Inventor
Donald D. Rao
Ewa Sitnicka
Stephen H. Bartelmez
Frederick S. Hagen
Original Assignee
Icogen Corporation
Seattle Biomedical Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icogen Corporation, Seattle Biomedical Research Institute filed Critical Icogen Corporation
Priority to AU50830/98A priority Critical patent/AU5083098A/en
Publication of WO1998018486A1 publication Critical patent/WO1998018486A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/355—Leptin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/39—Steroid hormones

Definitions

  • mice obesity (ob) gene encodes an adipose tissue-derived signalling factor for body weight homeostasis. Zhang et al . , Nature 372:425-432 (1994).
  • the ob gene product was subsequently named "leptin,” which means thin in Greek.
  • the leptin protein is proposed to function as part of a signalling pathway from adipose tissue that regulates the size of body fat deposits.
  • ob/ob mutant mice are hyperphagic and maintain a body mass eight times of the wild type animal.
  • the leptin molecule is 167 amino acids long and appears to be well conserved among vertebrates.
  • a cDNA clone encoding human leptin has been isolated and the amino acid sequence shows a high degree of identity between human and mouse.
  • mRNA for leptin is only expressed in white adipose tissue (WAT) , and leptin has the properties of a secreted hormone.
  • WAT white adipose tissue
  • the receptor for leptin has been identified by an expression cloning method (Tartaglia et al . , Cell 83: 1263- 1271 (1995) ) . It is a single transmembrane-spanning receptor that appears most related to the gpl30 signal-transducing component of the IL-6 receptor, a signal transducer shared by the IL-6, LIF, OM, and IL-11 receptor systems. Strong evidence indicate that the diabetes ( fo) gene encodes the leptin receptor (Chen et al . , Cell 84: 491-495 (1996); Chua et al., Science 271: 994-996 (1996); Lee et al .
  • the db/db mutation is the result of abnormal splicing of the leptin receptor.
  • At least five alternatively spliced mRNA have been identified in mouse and four in humans, with only one form (the long form) having a signal transducing cytoplasmic domain (Lee et al . , supra) .
  • the leptin receptor has a much broader tissue distribution than leptin, and has been detected most strongly in lung and kidney, (Tartaglia et al . , supra) .
  • mRNA for leptin receptor can also be detected in brain, hypothalamus, testis and adipose tissue (Lee et al . , supra) .
  • Cioffi et al . Nature Med. 2: 285-589 (1996).
  • Ghilardi et al . Proc . Natl. Acad. Sci . USA 93:6231-6235 (1996), has reported the presence of leptin receptor sequence in bone marrow and many other lymphoid tissues . The receptor appears to be abundant in peripheral and mesenteric lymph nodes.
  • HSC Hematopoietic stem cells
  • the hematopoietic system contains a core of stem cells (HSC) that can expand dramatically on demand and can differentiate to provide all of the myelolymphoid lineages of the circulating population.
  • HSC stem cells
  • CFU-S transplantable colony forming cell
  • the cells fractionated by these methods have been studied for proliferative capacity, pluripotency and purity using such measurements as capacity to proliferate and differentiate in vi tro and/or in vivo .
  • the most stringent of these tests is the ability to repopulate all myelolymphoid lineages of a lethally irradiated animal (Metcalf and Moore, Haematopoietic Cells. Frontiers of Biology Series. North Holland, Amsterdam (1971), p. 71.
  • Other approaches have used the transplantation of unfractionated but genetically distinct marrow donor cells, based on either alloenzymes or the random insertion sites of retrovirally transferred genes (Harrison et al., Proc. Natl. Acad. Sci.
  • HSC Distinct HSC subpopulations were demonstrated that ranged from the ability to short-term (weeks to months) repopulate (STR-HSC) to longterm (> 1 year) repopulate (LTR-HSC) lethally irradiated mice (see Bartelmez et al . , supra) .
  • LTR-HSC LTR-HSC
  • STR-HSC STR-HSC
  • the ability to repopulate transplanted mice and to proliferate clonally in vi tro have been studied (Wolf et al . , Exp . Hematol . 21: 614-622 (1993)).
  • One LTR-HSC is capable of replenishing the marrow of a lethally irradiated mouse. This is accomplished by administering a single LTR-HSC from a male mouse along with STR-HSC from a female mouse to a lethally compromised female mouse.
  • the one LTR-HSC must be accompanied by STR-HSC to supply the short term needs for blood cells until the LTR-HSC has sufficiently proliferated to support the development of all the blood cell types to allow for long-term survival.
  • the replenishing of the marrow by male donor cells is validated by analysis of the marrow cells for presence of the Y chromosome or the congenic allele Ly 5.1.
  • LTR-HSC can fully repopulate the marrow of a mouse. This indicates significant self renewal of the LTR-HSC which must occur in order for one cell to fully potentiate the whole marrow system.
  • the presence of LTR-HSC in such a repopulated mouse can be validated by isolation of LTR-HSC from such a repopulated mouse as well as a normal mouse (Jones et al . , supra) .
  • LTR-HSC may be depleted if marrow cells are serially passaged through a number of lethally irradiated mice, indicating that continuous incessant demand for developing cells may deplete the supply of LTR-HSC.
  • hematopoiesis The process of hematopoiesis is regulated by a group of proteins known as hematopoietic growth factors including colony stimulating factors and interleukins .
  • hematopoietic growth factors including colony stimulating factors and interleukins .
  • Growth and development of hematopoietic cells is under strict regulation by these factors requiring constant presence of factor (s) for continued growth and differentiation.
  • factor s
  • Different levels and/or mixtures of factors may account for developmental determination at points in stem cell differentiation and maturation of progeny.
  • the effects of these factors are mediated through cell surface proteins known as hematopoietic receptors.
  • SCF stem cell factor
  • GM-CSF granulocyte macrophage colony stimulating factor
  • M-CSF macrophage colony stimulating factor
  • the primary control mechanisms by which the hematopoietic hierarchy is maintained are unknown. For example, vertebrates maintain what appears to be a very finely regulated production of all blood cell types that is generated by a hierarchy of marrow cells that progressively give rise to daughter cells with less proliferative and differentiation potential. This hierarchy may be maintained at all levels by varying degrees of self-replication within a "compartment,” and also by differentiation of cells into and out of a compartment. It would be useful to identify self-replication factors (SRFs) in these compartments. Most hematopoietic growth factors act as potent mediators of differentiation, and as such are classic differentiation factors (DFs) .
  • SRFs self-replication factors
  • the most primitive cells of the stem cell compartment are unique in that there are no cells that can differentiate into this compartment .
  • a differentiation event occurs within the stem cell compartment when LTR-HSC divide and generate STR-HSC which appear to have limited clonal lifespans (see, Bartelmez et al . , Exp Hematol 2:861-862 (1991)).
  • the LTR-HSC appear to have an unlimited lifespan which could be accounted for through an asymmetrical division (one daughter cell is a replicate of the mother cell, the other enters the hematopoietic pool of cells with limited clonal lifespans) .
  • only a symmetrical division of self replication would lead to clonal expansion.
  • TGF- ⁇ l Transforming growth factor-beta-1 (TGF- ⁇ l) has been identified as an extrinsic and intrinsic (Sitnicka et al . , Blood 88: 82-88 (1996)) mediator of self-renewal of LTR-HSC.
  • LTR-HSC In culture, in the presence of a known growth factor or combination of factors, LTR-HSC do not undergo self renewal. Culturing stem cells in the presence of cell condition media or on feeder cells has also not been reported to stimulate self renewal of LTR-HSC in culture (Knobel et al., EXP . Hematol . 22: 1227-1235 (1994); van der Loo and Ploemacher, Blood 85: 2598-2606 (1995). To confirm the existence of such a factor, the cDNA encoding this activity must be isolated.
  • the present invention provides, in one aspect, methods for increasing the number of hematopoietic precursor cells by exposing the precursor cells to leptin, thereby increasing the number of precursor cells relative to the number of cells initially present.
  • the exposure of the cells can occur either in vitro or in vivo.
  • the hematopoietic precursor cells can be separated from mature hematopoietic cells present in a blood product, such as bone marrow, umbilical cord blood, or peripheral blood, prior to exposing the hematopoietic precursor cells to leptin.
  • the hematopoietic precursor cells are stem cells or progenitor cells.
  • the hematopoietic precursor cells which are exposed to the leptin are lin- cells, and more preferably are a lin-/c-kit+ fraction thereof, and include a lin-/Rh low/c- kit+ and lin-/Rh high/c-kit-i- cellular fraction.
  • lin- cells preferably are a lin-/c-kit+ fraction thereof, and include a lin-/Rh low/c- kit+ and lin-/Rh high/c-kit-i- cellular fraction.
  • At least one exogenously added growth factor such as G-CSF, GM-CSF, IL-1, IL-3, IL-4, IL-6, IL-7, IL-9, IL-10, IL-11, IL-12 or TGF- ⁇ , will be included.
  • the invention provides a method for maintaining the number of hematopoietic stem cells in vitro, comprising exposing the stem cells to leptin and culturing the cells. The number of stem cells relative to the number of cells initially present is thereby maintained.
  • the hematopoietic stem cells can be separated from mature hematopoietic cells present in a blood product, such as marrow or umbilical blood, prior to exposing the stem cells to leptin.
  • the hematopoietic stem cells are typically lin-/c- kit+ cells or a lin-/Rh low/c-kit+ or lin-/Rh high/c-kit+ fraction thereof.
  • the invention provides a method for sustaining primitive hematopoietic stem cells in vitro without substantial proliferation or differentiation.
  • the primitive hematopoietic stem cells are exposed to leptin and then cultured, and the number of primitive stem cells relative to the number of cells initially present is sustained, e.g., for at least five to seven days.
  • the primitive hematopoietic stem cells are lin-/Rh low/Ho low/c-kit+ or lin-/c-kit+, and may be separated from mature hematopoietic cells present in a blood product prior to exposing the primitive hematopoietic stem cells to leptin.
  • the primitive hematopoietic stem cells can be subsequently stimulated to proliferate and differentiate.
  • the invention provides a method for inhibiting the proliferation of hematopoietic cells that have been stimulated by IL-3.
  • IL-3 stimulated hematopoietic cells are exposed to leptin, thereby inhibiting the proliferation of cells induced by IL-3.
  • the hematopoietic cells can be in fractionated or unfractionated bone marrow.
  • the invention provides a method for increasing the number of hematopoietic cells in a mammalian host.
  • the hematopoietic precursor cells of the host are exposed to leptin, either in vitro or in vivo, thereby increasing the number of precursor cells relative to the number of cells initially present.
  • the hematopoietic precursor cells can be separated from mature hematopoietic cells present in the blood product such as bone marrow prior to exposing the cells to leptin.
  • the hematopoietic precursor cells, of a lin- fraction, such as lin-/c-kit+ are obtained from the host prior to initiation of cytotoxic therapy.
  • a composition for sustaining or expanding the number of hematopoietic precursor cells comprises a nutrient medium and leptin.
  • the composition further comprises at least one exogenously supplied growth factor, such as G-CSF, GM-CSF, SCF, IL-1, IL- 3, IL-4, IL-6, IL-7, IL-9, IL-10, IL-11, IL-12 or TGF-?.
  • Fig. 1 shows the detection of leptin receptor mRNA expressed in bone marrow cells and hypothalamus, where 1 ⁇ g, 0.1 ⁇ g and 0.01 ⁇ g of DNA from cDNA library prepared from RNA of hypothalamus (lanes a, d, g, respectively) , bone marrow (lanes b, e, h, respectively) and ALVA 31 prostrate tumor cells (lanes c, f, i, respectively) were used as template for PCR amplification using primers which recognize a common sequence found in known forms of leptin receptor.
  • the amplified DNA was fractionated by 1 % agarose gel electrophoresis, stained with ethidium bromide, excited with
  • FIG. 2 shows the detection of multiple forms of leptin receptor mRNA expressed in bone marrow, where 1 ⁇ g of DNA from the bone marrow cDNA library was used for PCR amplification with primers specific for each alternatively spliced forms of leptin receptor.
  • Lanes a, b, c, d, and e show Ra, Rb, Re, Rd and Re forms of leptin cDNA, respectively, and a 100 bp ladder was used as marker DNA.
  • the present invention provides compositions and methods for maintaining and increasing the number of hematopoietic precursor cells in vitro and in vivo.
  • the present invention provides methods to sustain the growth and differentiation of hematopoietic precursor cells in vivo or ex vivo by exposing the cells to leptin or leptin-like proteins or analogs which are capable of stimulating leptin receptor-mediated activity in these cells.
  • Leptin and analogs thereof can also be used in the present invention to sustain self replication of primitive hematopoietic stem cells in vitro, to inhibit IL-3 stimulated differentiation of hematopoietic cells, and to enrich for hematopoietic cells expressing leptin receptor in a mixed population of hematopoietic cells.
  • leptin can be used synergistically with other exogenously added hematopoietic growth factors to support and expand hematopoietic stem and progenitor cells.
  • cultured hematopoietic cells can be used as an important source of proliferating cells to reconstitute a patient's blood-clotting and infection-fighting functions subsequent to therapy.
  • the ability to expand hematopoietic precursor cells and their precursors in vitro relieves dependence on bone marrow aspiration or multiple aphereses as the only means of obtaining sufficient cells for transplantation.
  • hematopoietic precursor cells are typically separated from a blood product, such as bone marrow, peripheral blood, or umbilical cord blood of a patient or donor, fetal peripheral blood and other sources.
  • a blood product such as bone marrow, peripheral blood, or umbilical cord blood of a patient or donor, fetal peripheral blood and other sources.
  • separation may be performed, for example, by depleting the blood product of cells that are committed to specific lineages based on their expression of one or more antigens which are present on substantially all lineage committed cells but are substantially absent from the lineage committed precursor cells. This lin- fraction is enriched for hematopoietic progenitor cells.
  • the lin- cells can be further fractionated, e.g., based on their expression of c-kit on the cell surface into c-kit+ and c-kit- fractions, as described in more detail below, and fractionated even further based again of differential expression of cell surface markers associated with a desired subpopulation.
  • the separated hematopoietic precursor cells may be stored frozen and thawed at a later date for inoculation into a suitable vessel containing a culture medium comprising a nutritive medium and leptin, optionally supplemented with a source of growth factors and, optionally, human or other animal plasma or serum.
  • the separated cells may be inoculated directly into culture without first freezing.
  • the resultant cell suspension is cultured in the presence of leptin under conditions and for a time sufficient to increase the number of hematopoietic precursor cells relative to the number of such cells present initially in the blood product.
  • the cells may then be separated by any of a variety of methods, such as centrifugation or filtration, from the medium in which they have been cultured, and may be washed one or more times with fresh medium or buffer.
  • the cells may be re-separated into lin- and lin+ fractions prior to resuspension to a desired concentration in a medium or buffer suitable for infusion.
  • the cells may then be infused into a patient or stored frozen for infusion at a later date.
  • separated precursor cells such as lin- cells and lin-/c-kit+ cells
  • lin- cells and lin-/c-kit+ cells will expand in number when cultured in the presence of medium containing leptin, enabling clinically practicable expansion and recovery of hematopoietic precursor cells.
  • the volumes of cells and culture fluids which must be handled are reduced to more manageable numbers.
  • a high degree of expansion can be achieved when one starts with separated lin- and lin-/c-kit+ cells, rather than with an unseparated blood product. This is believed to be due to the removal of cells otherwise present in the blood product, which inhibit expansion of the precursor cells. Under the conditions employed in the methods of this invention, cell recovery is greatly facilitated and viability is preserved.
  • the yield of hematopoietic precursor cells is increased.
  • the ability to sustain or expand hematopoietic precursor cells in vitro or in vivo by the compositions and methods of the present invention is expected to have tremendously important consequences for disease treatments which are inherently myelosuppressive or myeloablative, such as in cancer chemotherapy.
  • the lin- hematopoietic precursor (non-committed) cells include those which do not express antigens associated with neutrophils and activated macrophages (e.g., 7/4), B and pre-B lymphocytes (e.g., B220) , erythrocytes (YW 25.12.7), neutrophils and macrophages (e.g., GR-1) , T cells (Lyt-2) , T- helper cells (e.g., L3T4) , nucleated red blood cells (e.g.,
  • Lin- cells/c-kit-t- cells are those lin- cells which express c-kit antigen, as can be conveniently determined with an antibody to c-kit. Even further fractionation of lin- or lin-/c-kit+ cells based on amount of rhodamine 123 fluorescence can be used to provide fractions of lin-/Rh low or lin-/Rh low/c-kit-i- cells containing primitive hematopoietic cells, whereas cells of the Rh high fraction are less primitive.
  • the level of expression of the cell surface antigens will vary from one cell type to another.
  • a cell is operationally defined as lin-, c-kit+, or Rh low, if it expresses or does not express sufficient antigen to be detected by a given method of assay.
  • c-kit+ cells can be identified by flow microfluorimetry using a fluorescence-activated cell sorter (FACS) , by immunofluorescence or immunoperoxidase staining using a fluorescence or light microscope, by radioimmunoassay, or by immunoaffinity chromatography, among numerous other methods which will be readily apparent to one skilled in the art (see, for example, Lansdorp and Thomas (in Bone Marrow Processing and Purging, A. P.
  • Hematopoietic precursor cells can also be detected by various colony-forming assays, such as CFU-GM and CFU-S assays (see, e.g., Till and McCullough, supra ; Bradley and Metcalf, Aust . J. Exp. Biol. Med. Sci. 44: 287 (1966)).
  • Hematopoietic precursor cells including lin- and lin-/c-kit+ cells, may be obtained from any of a variety of blood products, including bone marrow, peripheral blood, umbilical cord blood, fetal liver, and spleen.
  • Bone marrow is a particularly rich source of precursor cells (1-2% of marrow) , but alternate sources may be preferable because of the discomfort associated with bone marrow aspiration. Bone marrow is typically aspirated from the iliac crest, but may be obtained from other sites (such as the sternum or vertebral bodies) if necessitated by prior or concurrent disease or therapy. Peripheral blood contains fewer precursor cells
  • peripheral blood mononuclear cells typically ⁇ 1% of peripheral blood mononuclear cells
  • the number of precursor cells circulating in peripheral blood can be increased by prior exposure of the donor to certain growth factors, such as, for example, G-CSF or SCF (.kit ligand (KL) ) , and/or certain drugs, such as, for example, cyclophosphamide or prednisone.
  • Peripheral blood collected from patients or donors who have been pretreated to increase the number of circulating hematopoietic precursor cells is referred to as having been "mobilized. "
  • leptin can be used to mobilize hematopoietic stem cells from the marrow to the peripheral blood for collection.
  • blood may be obtained by venipuncture or by one or more aphereses .
  • Precursor cells can also be obtained from umbilical cord blood at the time of delivery, either by simple gravity-induced drainage or manual expression.
  • Separation of precursor cells from more mature cells can be accomplished by any of a variety of methods known to those skilled in the art, including immunoaffinity chromatography (Basch et al . , J . Immunol . Methods 56:269 (1983)), fluorescence-activated cell sorting, panning (Wysocki and Sato, Proc. Natl. Acad. Sci. USA 15: 2844 (1978)), magnetic-activated cell sorting (Miltenyi et al . , Cvtometry 11: 231 (1990)), and cytolysis.
  • leptin is used to support survival of stem cells during the collection and processing of whole or fractionated marrow.
  • target e.g., CD34+ or lin-
  • non-target e.g., CD34- or lin+
  • separation is considered to have been accomplished if the target fraction is comprised of at least about 20% precursor cells, more often about 50% precursor cells, and preferably about 70% precursor cells.
  • the target fraction be comprised of less than about 5% platelets, 50% granulocytes, and 10% red cells and, preferably, less than about 1% platelets, 25% granulocytes, and 1% red cells.
  • Precursor cells may be positively selected or negatively selected.
  • positive selection is meant the capture of cells by some means, usually immunological, on the basis of their expression of a specific characteristic or set of characteristics (usually an antigen (s) expressed at the cell surface) .
  • CD34+ or c-kit-i- cells can be positively selected by any of the above methods (except cytolysis, which would result in destruction of the desired cells) on the basis of their expression of the c-kit antigen utilizing an anti-c-kit antibody, such as anti-human monoclonal antibody YB5.B8 (available from Pharmingen, Inc.), or anti-CD34 monoclonal antibodies which are also commercially available, e.g., monoclonal antibodies 12.8, My-10, or 8G12 (Becton Dickinson Co., Mountain View, CA) .
  • Negative selection means the exclusion or depletion of cells by some means, usually immunological, on the basis of their lack of expression of a specific characteristic or set of characteristics (again, usually a surface antigen) .
  • lin- cells can be negatively selected by any of the above methods on the basis of their lack of expression of lineage-defining antigens, such as CD19 (for B lymphocytes) , CD3 (for T lymphocytes) , CD56 (for NK cells) , CD4 (T-helper cells) , CD8 (cytotoxic T cells) , CD20 (macrophages) , CDllb (monocytes, granulocytes, neutrophils, macrophages, NK cells, and activated lymphocytes), CD33 (monocytes, activated T cells, myeloid progenitors) , glycophorin A (red blood cells and erythroid precursor cells), etc., utilizing antibodies to the above-mentioned and other lineage-defining antigens.
  • precursor cells can be separated from mature cells by a combination of negative and positive selection techniques.
  • a preferred combination of negative and positive selection techniques is comprised of a first selection for lin- cells utilizing a mixture of anti-lin+ antibodies as described above, followed by a second selection for c-kit+/lin- cells, using an anti-c-kit antibody to a determinant on the c-kit antigen.
  • Antibodies to determinants on the c-kit molecules are well-known in the literature (see, e.g., Ashman et al . , J. Cell. Physiol . 158: 545 (1994)) and are available from a variety of sources, including those mentioned above.
  • the advantage of this or other dual selection strategies is that the volume of cells which is placed into culture is smaller, more manageable, and more susceptible to stimulation and expansion by leptin.
  • the precursor cells are periodically (e.g., every 4-7 days) separated from more mature cells.
  • mature cells which include not only terminally differentiated blood cells, but cells of an intermediate lineage
  • Various methods may be used to periodically separate precursor from mature cells, for example, cells can be separated on an affinity column, incubated in a selected medium, and then subsequently reseparated in order to separate the precursor cells from the newly differentiated mature cells . Examples of methods and devices for selecting precursor cells, such as CD34+, or lin-/c-kit+ cells, are described in U.S. Patent Nos. 5,215,927, and 5,225,353, each of which is incorporated herein by reference.
  • precursor cells are inoculated into a culture medium comprised of a nutritive medium, any number of which, such as RPMI , TC 199, Ex Vivo-10, or Iscove's DMEM, along with a source of growth factors, will be apparent to one skilled in the art.
  • Proliferation and differentiation of precursor cells may be enhanced by the addition of various components to the medium, including a source of plasma or serum.
  • sources of plasma or serum are fetal bovine and human.
  • the amount of plasma or serum which is used will vary, but is usually between about 1 and 50% (by volume) of the medium in which the cells are grown, and more often between about 1 and 25%.
  • separated hematopoietic precursor cells are cultured in a nutritive medium and leptin.
  • the leptin is prepared as generally described in, e.g., Friedman et al . , International PCT publication WO 96/05309, incorporated herein by reference.
  • WO 96/05309 describes the preparation of isolated and purified leptin (alternatively described as OB polypeptide) , as well as nucleic acids encoding leptin and the amino acid sequences thereof, including human leptin polypeptides, and peptide fragments, derivatives and analogs.
  • leptin polypeptides for use in the methods of the present invention can be prepared by recombinant or synthetic means, as described in WO 96/05309.
  • Other leptin receptor recognition molecules can also be used in the present invention.
  • leptin analogs and mimetics including small molecule analogs, can be identified as leptin receptor agonists or antagonists as described in WO 96/05309.
  • a leptin receptor has been described in Tartaglia et al . , Cell 83:1263-1271 (1995), incorporated herein by reference.
  • the mimetics or analogs will typically have a biological activity of the leptin polypeptide, including but not limited to specific binding to a leptin receptor or antibody specific for a leptin molecule, or other recognition molecule; activation of signal transduction pathways; and/or induction (or inhibition by antagonists) of physiological effects mediated by the native leptin polypeptide in vivo or in vitro.
  • leptin includes molecules such as leptin mimetics and the like which have the same or similar effect as leptin as described herein, e.g., maintaining or expanding hematopoietic precursor cells, sustaining self-replication of primitive stem cells, inhibiting differentiation of hematopoietic precursor cells caused by IL-3, and improving the recovery of patients from radiation or chemotherapy.
  • the leptin can be used in the present invention as a purified preparation or as a component of a composition, including a mixture with other hematopoietic growth factors.
  • growth factors which may be employed in the medium are interleukins (IL) 1-15, erythropoietin (US Patent No.
  • stem cell factor also known as mast cell growth factor and c-kit ligand
  • G-CSF granulocyte colony stimulating factor
  • GM-CSF macrophage-colony stimulating factor
  • M-CSF macrophage-colony stimulating factor
  • TGF beta tumor necrosis factor alpha
  • TPO thrombopoietin
  • IFN alpha, beta, or gamma the interferons
  • FGF fibroblast growth factor
  • PDGF platelet-derived growth factor
  • IGF-1 and IGF-2 insulin-like growth factors
  • MPL megakaryocyte promoting ligand
  • Growth factors are commercially available, for example, from R & D Systems, Inc. (Minneapolis, MN) , Amgen, Inc. (Thousand Oaks, CA) , Immunex Corp. (Seattle, WA) , Genetics Institute (Cambridge, MA), and Genentech, Inc. (S. San Francisco, CA) , among other sources. Particularly preferred are combinations of growth factors, especially the combination of IL-3, G-CSF, and SCF. In general, the above-mentioned growth factors are purified or partially purified before they are added to the culture medium.
  • Non-naturally occurring growth factors can also be produced by recombinant DNA methods, and it will be evident to those skilled in the art that fusion proteins, combining multiple growth factor activities, can be readily constructed, for example, fusion proteins combining SCF activity with that of other growth factors such as IL-1, IL-6, G-CSF, and/or GM-CSF.
  • the amount of each growth factor to be used is determined empirically and will vary depending on the purity and method of production of the factors. Generally, concentrations between 0.5 and 100 ng/ml are sufficient, more often between 0.5 and 50 ng/ml.
  • the optimum amount of each factor should be determined in combination with the other factors to be used. This is because some growth factors can modulate the activity of other growth factors, necessitating that they be used sequentially rather than simultaneously, while in other instances, growth factors may act synergistically . Still other growth factors may enhance proliferation or differentiation along one pathway, while suppressing another pathway of interest. For example, as shown herein leptin suppresses the stimulation of proliferation that is stimulated by IL-3. Thus, leptin can be used in this situation to suppress the amplification of certain cell types, e.g., those which are IL-3 responsive, while permitting the amplification of others.
  • the medium may also be prepared with or without a source of serum or plasma. If used, the serum or plasma may be of human or other animal origin. Particularly preferred for cultivation of human cell is human autologous plasma or human AB " plasma. The amount of plasma or serum which is used will vary, but is usually between about 1 and 50% (by volume) of the medium in which the cells are grown, and more often between about 1 and 25%.
  • Separated precursor cells may be cultured in any vessel which is capable of being sterilized, is adapted or adaptable to gas exchange with the atmosphere, and is constructed of a material which is non-toxic to cells.
  • vessels suitable for this purpose are well-known in the art, including stirring flasks (Corning, Inc., Corning, NY) , stirred tank reactors (Verax, Riverside, NH) , airlift reactors, suspension cell retention reactors, cell adsorption reactors, and cell entrapment reactors, petri dishes, multiwell plates, flasks, bags and hollow fiber devices.
  • agitation it can be attained by any of a variety of means, including stirring, shaking, airlift, or end-over- end rotation.
  • the culture can also be maintained in suspension by matching the density of the culture medium to the density of the cells or microcarrier beads.
  • This invention provides methods of using leptin and pharmaceutical compositions comprising leptin for stimulating hematopoiesis in mammals, including humans. These compositions and methods are useful in promoting both long-term and short- term hematopoietic recovery and treating side effects of in a myelosuppressed or myeloablated host. Myelosuppression or myeloablation may occur as an isolated disorder, secondary to another disorder, or as a side effect resulting from a specific therapeutic regimen.
  • the leptin can be used alone or in conjunction with other treatments, e.g., G-CSF.
  • the leptin is typically administered in the form of a pharmacologically effective amount and a pharmaceutically acceptable carrier.
  • a pharmacologically effective amount is, in this case, an amount effective to promote the proliferation of hematopoietic cells, e.g., stem or progenitor cells, or increase the number of stem cells in the circulating blood.
  • the form, amounts and timing of administration generally are a matter for determination by the practitioner.
  • systemic administration in a liquid carrier by injection is preferred.
  • the pharmaceutical composition is delivered as a unit dosage form.
  • unit dosage forms for systemic administration include unit doses of injectable solutions. These compositions are useful in the therapeutic methods of this invention.
  • Therapeutic doses generally will be in the range of 0.1 ⁇ g/kg to 1.0 mg/kg of subject body weight per day, preferably 1.0 ⁇ g/kg to 100 ⁇ g/kg body weight per day, with the exact dose determined by the clinician according to accepted standards, taking into account the nature and severity of the condition to be treated, the subject's traits, etc. Determination of dose is within the level of ordinary skill in the art.
  • the protein may be administered for acute treatment, over one week or less, often over a period of one to three days or may be used in chronic treatment, over several months or years .
  • Bone marrow transplantation the transplantation of hematopoietic cells into the bone marrow of a subject
  • methods are provided for transplanting hematopoietic cells maintained and/or expanded with leptin into a subject.
  • Bone marrow transplantation is useful for replacing hematopoietic cells in subjects whose hematopoietic cells have been damaged or destroyed by, for example, disease, cancer therapy or other exposure to radiation.
  • bone marrow or peripheral blood progenitor (PBPC) cells are removed from a patient or a suitable donor prior to the patient's chemotherapy or radiation exposure and treated with leptin, optionally in combination with one or more other cytokines, as described above.
  • PBPC peripheral blood progenitor
  • marrow Prior to chemotherapy treatment, marrow can be stimulated with stem cell factor (SCF) or G-CSF to release early progenitor cells into peripheral circulation.
  • SCF stem cell factor
  • G-CSF G-CSF
  • progenitors can be collected and concentrated from peripheral blood and then treated in culture with leptin, optionally in combination with one or more other cytokines, including but not limited to SCF, G-CSF, GM-CSF, IL-6 or IL-11, to differentiate and proliferate into high-density megakaryocyte cultures, which can then be returned to the patient following high-dose chemotherapy.
  • the present invention can be used in methods of hematopoietic stem cell transplantation.
  • Procedures for obtaining hematopoietic stem cells, readministering them and repopulating marrow are widely used.
  • the cells are exposed to effective concentrations of leptin during these stages, including during cultivation. This treatment enhances repopulation of the marrow by stem cells upon subsequent readministration to the patient.
  • Leptin can also be used in methods of gene therapy where hematopoietic cells are targeted for introduction of one or more genes encoding expression product (s) .
  • Hematopoietic stem cells are often targets of gene therapy methods, but in the past it has been difficult to manipulate the stem cells in vitro without losing the sternness of the long term repopulating stem cells (LTR-HSC) .
  • LTR-HSC long term repopulating stem cells
  • the LTR-HSC must be altered in such a way that sternness has been maintained.
  • exposure of the LTR-HSC to leptin during collection and manipulation in vitro promotes survival and expansion of this cell population, thereby enhancing the long term effectiveness of the gene therapy procedure.
  • Suitable viral vectors include retroviral vectors (see Miller, Curr. Top. Microbiol . Immunol. 158: 1-24 (1992); Salmons and Gunzburg, Human Gene Therapy 4: 129-141 (1993); Miller et al . , Methods in Enzvmology 217: 581- 599, (1994)) and adeno-associated vectors (reviewed in Carter, Curr. Opinion Biotech. 3: 533-539 (1992); Muzcyzka, Curr . Top . Microbiol . Immunol . 158: 97-129 (1992)).
  • viral vectors that may be used within the methods include adenoviral vectors, herpes viral vectors and Sindbis viral vectors, as generally described in, e.g., Jolly, Cancer Gene Therapy 1:51- 64 (1994); Latchman, Molec . Biotechnol . 2:179-195 (1994); and Johanning et al . , Nucl . Acids Res. 23:1495-1501 (1995), each incorporated herein by reference.
  • the choice of vector will rely in part on the requirement for cellular replication, the disease state that is being treated and the size of the gene to be transferred.
  • the genes are introduced into cells of the individual in vivo by means of expression vectors.
  • the genes are introduced into cells ex vivo, and transfected cells that express and secrete leptin are administered to the subject.
  • PCR primers were initially designed according to the mouse and human leptin receptor sequences to detect receptor cDNA sequence in a hypothalamic cDNA library.
  • DNA from the cDNA library was first denatured by alkaline treatment, diluted, and subjected to PCR amplification with leptin receptor specific sequences.
  • a cDNA library constructed from bone marrow tissue RNA was included as a control.
  • total RNA was extracted from mouse bone marrow tissue by the method of Chomczynski and Sacchi, Analyt . Biochem. 162: 156- 169 (1987) and using RNAzol solution supplied by the manufacturer (Tel-Test, Inc. Friendswood, Tx) .
  • RNAzol solution Tissues were deposited directly into appropriate volume of RNAzol solution. Extraction of RNA followed the procedures recommended by the manufacturer with slight modifications. Two additional phenol-chloroform extractions were routinely performed on the RNA isolated by the RNAzol method to ensure the purity of RNA.
  • Primers for PCR were designed based on leptin receptor sequence using the GeneWorks program (IntelliGenetics) . Primers were purchased from Gibco/BRL.
  • the PCR primer set sequence was designed to amplify sequence from amino acid #8 through amino acid #248 at the 5' end of the coding region of leptin receptor, and to detect all alternatively spliced forms of leptin receptor mRNA.
  • the pair of primers had the following sequence: forward primer, 5' TGTGGTTTTGTTACAYTGGG 3' [Seq ID No: 1] ; reverse primer, 5' TGTGAYTTCCATATGCAATCC 3' [Seq ID No: 2] .
  • PCR was performed with standard method recommended by the manufacturer on a Gene Amp 2400 system (Perkin-Elmer) .
  • Taq polymerase and reagents were purchased from Perkin-Elmer.
  • PCR was generally done with 25-30 cycles of amplification. PCR product was analyzed on a 1% agarose gel.
  • RT-PCR reverse transcription-PCR
  • the RT reaction followed recommendations of the manufacturer.
  • a portion of, or diluted cDNA was used for PCR depending on the abundance of the mRNA.
  • PCR amplification was as described above, and RT-PCR product was analyzed on an appropriate percentage of agarose gel .
  • Fig. 1 The results obtained with the hypothalamic cDNA library and cDNA libraries constructed from bone marrow RNA and from ALVA31 prostate tumor cell RNA are shown in Fig. 1.
  • a 720 bp band was detected from 1 ⁇ g and 0.1 ⁇ g of hypothalamic cDNA library DNA (Fig. 1, lanes a and d) .
  • the 720 bp band was also amplified from DNA of the bone marrow library (Fig. 1, lanes b, e, and h) .
  • the intensity of the 720 bp DNA band amplified from the bone marrow library was greater than from the hypothalamic library.
  • the 720 bp band could be detected from as little as 0.01 ⁇ g of the total bone marrow library DNA.
  • the 720 bp band was isolated from agarose gel and partially sequenced to confirm its identity as the leptin receptor sequence.
  • the primer set used for the initial experiments amplified all forms of leptin receptor.
  • Alternatively spliced forms of leptin receptor mRNA are not revealed by this analysis.
  • which alternatively spliced form of leptin receptor mRNA is expressed in bone marrow tissue was determined.
  • Specific PCR primer sets have been used to differentially detect all five forms of alternatively spliced mRNA (Lee et al . , Nature 379: 632-635 (1996)) .
  • one goal was to identify cell types within the population that express the leptin receptor mRNA by using the RT-PCR method, based on the assumption that cells expressing the leptin receptor will be able to respond to leptin.
  • Cell lines screened included WEHI-3 cells, 32D-J558 cells, EML cells and MPRO cells. As a result of the screening, only WEHI-3 cells were found to express the receptor sequence.
  • WEHl-3 is a mouse yelomonocytic leukemia cell line. WEHI-3 cellular RNA was then used to determine the sensitivity of detection by the RT-PCR method and to determine whether the leptin receptor mRNA was the long or short form.
  • the WEHI-3 RNA was also used to standardize and improve the sensitivity of detection by RT-PCR method.
  • a bone marrow library was constructed with RNA isolated from bone marrow of an animal treated with 5-Fluorouracil (5-FU) to enrich for hematopoietic stem cell population and to determine whether 5-FU would enrich for the cells expressing leptin receptor mRNA.
  • 5-FU treatment ablates dividing cells and therefore enriches for precursor and mature cells of the bone marrow (Bartelmez and Stanley, J. Cell. Phvsiol . 122:370-378 (1985)).
  • Male and female F x hybrid mice from the cross C57B1/6 X DBA/2 were used.
  • mice Three-to-six-month old mice came from a NIA-derived breeding colony maintained under strict specific pathogen-free conditions and routinely tested and confirmed to be free of all known mouse pathogens. Mice of about 20 g were either treated with a single injection of 3 ⁇ g 5-FU or not treated, and bone marrow cells were harvested 3 days after treatment . To harvest bone marrow cells, mice were sacrificed, femurs and tibias were removed aseptically and repetitively flushed of marrow with phosphate buffered saline (PBS) , 2% fetal bovine serum (FBS) (Biocel, Collinso Dominguez, CA) .
  • PBS phosphate buffered saline
  • FBS fetal bovine serum
  • the low density bone marrow cells were isolated on a gradient by layering 5 ml aliquots of 10 7 cells/ml over 4.0 ml Nycodenz (1.080 g/ml) (Nycomed, Oslo, Norway). Cells were centrifuged 20 min at 400 x g, collected from the interface and washed twice with collection medium at 4°C.
  • Hematopoiesis is regulated by a group of proteins known as hematopoietic growth factors and the constant presence of these factors is required for the proliferation and differentiation of hematopoietic cells.
  • the effect of hematopoietic growth factors is mediated through the specific cell surface proteins known as hematopoietic growth factor receptors .
  • the presence of leptin receptor sequence was detected in the bone marrow cDNA library. To explore the possible regulatory effect of leptin on hematopoiesis, the mitogenic effect of leptin on hematopoietic cells was assessed.
  • Bone marrow was fractionated by depleting the marrow of cells that are committed to specific lineages using a cocktail of antibodies against cell surface lineage specific antigens. This "lin- fraction" is highly enriched for hematopoietic progenitor cells. Lineage committed cell depletion was performed as follows: Three-to-six-month-old male BDF X mice (C57B1/6 X
  • DBA/2) were sacrificed, femurs and tibias were removed aseptically and receptively flushed of marrow with PBS with 2% FBS .
  • Low density cells were first isolated on a gradient by layering 5-ml aliquots of 10 7 unfractionated cells/ml over 4.0 ml Nycodenze (1.080 g/ml) (Nycomed, Oslo, Norway). Cells were centrifuged 20 minutes at 400xg, collected from the interface and washed with a lOx excess of PBS with 2% FBS.
  • Lineage committed cells were then removed by the antibody mediated magnetic bead depletion using the following rat anti-mouse monoclonal antibodies: anti-7/4 (neutrophils and activated macrophages; obtained from S. Gordon, Oxford, UK), anti- YW25.12.7 (blasts and nucleated erythroid cells; obtained from I. Bertoncello, Peter MacCallum Cancer Institute, Melbourne, Australia) .
  • Antibodies purchased from PharMingen (San Diego, CA) were anti-Terl-19 (nucleated erythroid cells) , anti-B220 (B and pre-B lymphocytes), anti-Mac-1 (granulocytes, macrophages) and anti-Gr-1 (granulocytes, monocytes) .
  • Cells were then transferred into 50 ml centrifuge tubes (Corning) and rosetted with magnetic beads coated with sheep anti-rat IgG (Dynabeads M-450, Dynal, Inc., Great Neck, NJ) in the following manner: to an equal volume of cells (350xl0 6 cells/ 3.5 ml maximum per tube), lOx the number of magnetic beads was added dropwise to the cell suspension and mixed gently with a pipette. The suspension was centrifuged at 20xg for 3 min, then vigorously resuspended and transferred to a 15 ml polypropylene tube. Then 4 ml of PBS with 10% was added to prevent beads trapping and a tube was placed into the Dynal magnet for 3 min.
  • sheep anti-rat IgG Hynabeads M-450, Dynal, Inc., Great Neck, NJ
  • the pre- fractionated cells were analyzed and sorted on a FACStar Plus flow cytometer (Becton Dickinson, San Jose, CA) equipped with dual argon lasers, and an automated cell delivery unit (ACDU) .
  • Cells were kept chilled at 4°C with a recirculating water bath.
  • Monochromatic light at 351-364 nm and 488 nm was used for Ho and Rh 123 excitation, respectively.
  • Forward light scatter was detected using 488bpl0 and ND 1.0 filters.
  • Rhodamine 123 emission was detected using a 530bp20 filter, PE emission using a 575bp20 filter, propidium iodide emission using a 610 lp filter, and Hoechst emission using 395bp20, 485bpl5, or a 515 lp filter, as indicated.
  • the lin-/Rh low/c-kit+ fraction contains primitive hematopoietic cells, whereas cells in the Rh high fraction are less primitive.
  • the different bone marrow fractions were then expose to leptin.
  • Table 2 the single cell culture system was used to determine the direct effect on the target cell population and to measure the cloning efficiency (the proportion of dividing cells) .
  • IMDM Iscove's modified Dulbecco's medium
  • HS horse serum
  • HC hydrocortisone
  • antibiotics penicillin/ streptomycin
  • Growth factors were used at the following concentrations: 50 ng/ml of SCF, 20 ng/ml of IL-6, 100 ng/ml of IL-3 in triple cytokine combination and 400 ng/ml of IL-3 used as a single growth factor.
  • cells were cultured for 2-3 weeks. The use of U-bottom plates facilitated the settling of single cells to the bottom center, which allowed direct observation. Clones ranging from 2-64 cells could be directly enumerated. The number of cells per well were directly counted using a phase contrast microscope at 200 x magnification. Where indicated, single cell survival was determined by trypan blue exclusion coupled with the ability of live cells to highly refract light. Cell differentials were performed by counting cytospin preparations on slides stained by the Giemsa-Wright method.
  • Table 2 shows that leptin had a direct effect on cells from both the lin-/c-kit+ and lin-/Rh high/c-kit+, bone marrow fractions enriched for progenitor cells, where a substantial proportion of cells (20+5% and 22+6% of cells, respectively) proliferated in response to leptin. After 7 days of culture in leptin (100 ng/ml) , the proliferating clones reached the size of 100-200 cells per clone, corresponding to 7-8 cell divisions.
  • lin-/c-kit + bone marrow fraction contains cells that are direct target cells for leptin.
  • lin-/c-kit+ cells were grown in the presence of leptin at different cell concentrations for seven days and the cell number then counted. The indicated number of lin- or lin-/c-kit+ cells was directly deposited from the sorter into 96 U-bottomed culture plates containing medium alone or medium with 200 ng/ml leptin.
  • leptin had an indirect effect on cell proliferation.
  • Table 4 the rate of the proliferative response to leptin increased significantly with increased number of lin- cells plated in the presence of leptin at day 0. This suggests that leptin induces the production of other hematopoietic growth factor (s) that stimulate proliferation on lin- cells.
  • s hematopoietic growth factor
  • hematopoietic progenitor cells give rise into functionally mature and differentiated blood cells, their proliferation and differentiation is dependent on the presence of specific hematopoietic growth factors.
  • the number of progenitor cells can be assessed by colony formation in agar in the presence of hematopoietic growth factors.
  • leptin the effect of leptin on the generation of hematopoietic progenitor cells was determined.
  • Different bone marrow fractions were grown in the presence of medium alone or leptin for 7 days at the different cell concentration. After this time, all the cells were transferred into the agar cultures containing IL-3, IL-6, and SCF and the number of progenitor cells was determined after additional 14 days of culture.
  • rhuIL-6 Human IL-6 (rhuIL-6) was obtained from Immunex Corp., Seattle, WA, and rat SCF was obtained from Amgen Inc., Thousand Oaks, CA.
  • Table 5 shows the number of progenitor cells derived from different bone marrow fractions in the presence of leptin. No progenitors were generated from lin-/c-kit- fraction, and no progenitors were seen in any of tested fractions after 7 days culture in medium alone. Thus, it appears that the number of progenitors detected in the presence of leptin was dependent on the number of lin- and lin-/Rh high/c-kit+ plated. In both of these fractions, progenitor cells were generated when 250 cells were put in the culture with leptin at day 0.
  • leptin has an effect on the generation of hematopoietic progenitor cells, either on the self replication of progenitors cells and/or the generation of progenitor cells from less mature pre-progenitor cells.
  • Single lin- /lowRh/lowHo/c-kit+ cells were directly deposited from the sorter into 96-well U-bottomed plates containing medium alone or medium with 100 ng/ml or 1 pg/ml leptin. The presence of cells in the well was verified by microscopic examination. After seven days cell viability was estimated by the exclusion of trypan blue and/or by the ability to proliferate in response to growth factors (50 ng/ml IL-3, 50 ng/ml SCF, and 20 ng/ml IL-6) . Data represent mean values ⁇ SD from 3-7 independent experiments, where 80-90 single cells were analyzed. These results indicate that leptin acts as surviving factor for a subpopulation of stem cells.
  • a double-layer nutrient agar culture consisting of a 1 ml underlayer of 0.5% agar plus hematopoietic growth factors: rrSCF (50ng/ml) , rmIL-3 (115ng/ml) , rhIL-1 (20ng/ml) , rhCSF-1 (500U/ml) and 0.5 ml overlay of 0.3% agar plus target cells in 35-mm Petri dishes was used.
  • IL-3 is an important growth factor for a wide variety of bone marrow cells that are at the different stages of hematopoietic cell differentiation.
  • the results demonstrate that leptin has an inhibitory effect on colony formation that occurs in different bone marrow fractions in response to IL-3.
  • Table 8 different bone marrow fractions were grown in agar in the presence of IL-3 and different concentrations of leptin. After 14 days of culture, the number of colonies was estimated.
  • leptin affects hematopoiesis in different ways and can act on cells at different stages of differentiation.
  • leptin acts as a surviving factor for a subpopulation of primitive hematopoietic stem cells.
  • the generation of progenitor cells occurs.
  • Leptin also inhibits the proliferative response to IL-3 in wide variety of bone marrow cells, and leptin acts as direct mitogen for a subpopulation of lin-/c-kit+ cells.
  • MOLECULE TYPE cDNA
  • xi SEQUENCE DESCRIPTION: SEQ ID NO : 6 : TGGATAAACC CTTGCTCTTC A 21

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Developmental Biology & Embryology (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Selon la présente invention, l'exposition à la leptine de cellules précurseurs hématopoïétiques en augmente les quantités. Les cellules précurseurs hématopoïétiques, telles que les cellules souches et notamment celles issues d'une fraction lin-/c-kit+, peuvent être séparées des cellules hématopoïétiques mures présentes dans un produit sanguin tel que la moelle osseuse, avant exposition à la leptine. Le nombre de cellules souches hématopoïétiques in vitro peut également être conservé par exposition à la leptine, les cellules souches hématopoïétiques souches primitives pouvant être conservées sans prolifération ou différentiation notable. De la même façon, il est possible d'inhiber, grâce à un traitement à la leptine, la stimulation à médiation IL-3 des cellules hématopoïétiques. L'invention concerne également l'utilisation d'une composition contenant de la leptine pour conserver ou accroître le nombre de cellules hématopoïétiques. Ces procédés et compositions, qui favorisent la survie de cellules souches pendant la collecte et le traitement, permettent de mobiliser les cellules souches au profit de la circulation périphérique, de développer in vitro les cellules souches, de perfectionner la transplantation de moelle osseuse et d'accroître l'efficacité de la thérapie génique destinée au repeuplement à long terme des populations de cellules souches hématopoïétiques (LTR-HSC).
PCT/US1997/018875 1996-10-25 1997-10-24 Utilisation de la leptine pour stimuler l'hematopoiese WO1998018486A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU50830/98A AU5083098A (en) 1996-10-25 1997-10-24 Use of leptin to stimulate hematopoiesis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73679396A 1996-10-25 1996-10-25
US08/736,793 1996-10-25

Publications (1)

Publication Number Publication Date
WO1998018486A1 true WO1998018486A1 (fr) 1998-05-07

Family

ID=24961321

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/018875 WO1998018486A1 (fr) 1996-10-25 1997-10-24 Utilisation de la leptine pour stimuler l'hematopoiese

Country Status (2)

Country Link
AU (1) AU5083098A (fr)
WO (1) WO1998018486A1 (fr)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999053939A1 (fr) * 1998-04-20 1999-10-28 Mayo Foundation For Medical Education And Research Traitement de l'osteoporose par la leptine
WO2000011173A1 (fr) * 1998-08-21 2000-03-02 Albany Medical College Peptides de type leptine
US6541604B1 (en) 1996-01-08 2003-04-01 Genentech, Inc. Leptin receptor having a WSX motif
EP1315510A2 (fr) * 2000-07-31 2003-06-04 New York Medical College Procedes et compositions permettant la reparation et/ou la regeneration de myocarde endommage
WO2003055989A3 (fr) * 2001-12-21 2003-10-30 Mount Sinai Hospital Corp Compositions cellulaires et procedes de preparation et d'utilisation associes
US7074397B1 (en) 1996-01-08 2006-07-11 Genentech, Inc. Method for enhancing proliferation or differentiation of a cell using ob protein
US7208572B2 (en) 1998-08-21 2007-04-24 Albany Medical College Leptin-related peptides
WO2008056963A1 (fr) * 2006-11-10 2008-05-15 Chanil Moon Procédé permettant la prolifération de cellules souches au moyen de leptine
US7524937B2 (en) 1996-01-08 2009-04-28 Genentech, Inc. WSX receptor agonist antibodies
US7875587B2 (en) 1999-03-29 2011-01-25 Uutech Limited Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
EP2330125A2 (fr) 2005-08-11 2011-06-08 Amylin Pharmaceuticals, Inc. Polypeptides hybrides ayant des propriétés sélectionnables
EP2330124A2 (fr) 2005-08-11 2011-06-08 Amylin Pharmaceuticals Inc. Polypeptides hybrides ayant des propriétés sélectionnables
EP2390264A1 (fr) 2005-02-11 2011-11-30 Amylin Pharmaceuticals Inc. Analogues de GIP et polypeptides hybrides de GIP aux propriétés sélectionnables
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
EP2417980A1 (fr) 2004-02-11 2012-02-15 Amylin Pharmaceuticals Inc. Polypeptides hybrides présentant des propriétés pouvant être choisies
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
US8497240B2 (en) 2006-08-17 2013-07-30 Amylin Pharmaceuticals, Llc DPP-IV resistant GIP hybrid polypeptides with selectable properties

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BLOOD, 01 August 1995, Vol. 86, No. 3, PARK et al., "Primitive Human Hematopoietic Precursors Express Bcl-x But Not Bcl-2", pages 868-876. *
CURRENT BIOLOGY, 01 September 1996, Vol. 6, No. 9, BENNETT et al., "A Role for Leptin and Its Cognate Receptor in Hematopoiesis", pages 1170-1180. *

Cited By (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7074397B1 (en) 1996-01-08 2006-07-11 Genentech, Inc. Method for enhancing proliferation or differentiation of a cell using ob protein
US7524937B2 (en) 1996-01-08 2009-04-28 Genentech, Inc. WSX receptor agonist antibodies
US6541604B1 (en) 1996-01-08 2003-04-01 Genentech, Inc. Leptin receptor having a WSX motif
WO1999053939A1 (fr) * 1998-04-20 1999-10-28 Mayo Foundation For Medical Education And Research Traitement de l'osteoporose par la leptine
US7208572B2 (en) 1998-08-21 2007-04-24 Albany Medical College Leptin-related peptides
US6777388B1 (en) 1998-08-21 2004-08-17 Clf Medical Technology Acceleration Program, Inc. Leptin-related peptides
US7790683B2 (en) 1998-08-21 2010-09-07 Albany Medical College Leptin-related peptides
US8022189B2 (en) 1998-08-21 2011-09-20 Albany Medical College Isolated antibodies against biologically active leptin-related peptides
US7186694B2 (en) 1998-08-21 2007-03-06 Albany Medical College Leptin-related peptides
US7786265B2 (en) 1998-08-21 2010-08-31 Albany Medical College Isolated antibodies against biologically active leptin-related peptides
WO2000011173A1 (fr) * 1998-08-21 2000-03-02 Albany Medical College Peptides de type leptine
US8067545B2 (en) 1998-08-21 2011-11-29 Albany Medical College Isolated antibodies against biologically active leptin-related peptides
US7875587B2 (en) 1999-03-29 2011-01-25 Uutech Limited Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
EP1315510A2 (fr) * 2000-07-31 2003-06-04 New York Medical College Procedes et compositions permettant la reparation et/ou la regeneration de myocarde endommage
EP1315510A4 (fr) * 2000-07-31 2005-08-03 New York Medical College Procedes et compositions permettant la reparation et/ou la regeneration de myocarde endommage
WO2003055989A3 (fr) * 2001-12-21 2003-10-30 Mount Sinai Hospital Corp Compositions cellulaires et procedes de preparation et d'utilisation associes
US7625752B2 (en) 2001-12-21 2009-12-01 Mount Sinai Hospital Cellular compositions and methods of making and using them
EP2422807A2 (fr) 2004-02-11 2012-02-29 Amylin Pharmaceuticals Inc. Polypeptides hybrides présentant des propriétés pouvant être choisies
EP2417980A1 (fr) 2004-02-11 2012-02-15 Amylin Pharmaceuticals Inc. Polypeptides hybrides présentant des propriétés pouvant être choisies
US9453063B2 (en) 2004-02-11 2016-09-27 Amylin Pharmaceuticals, Llc. Hybrid polypeptides with selectable properties
US8697647B2 (en) 2004-02-11 2014-04-15 Odile Esther Levy Hybrid polypeptides with selectable properties
EP2422806A2 (fr) 2004-02-11 2012-02-29 Amylin Pharmaceuticals Inc. Polypeptides hybrides présentant des propriétés pouvant être choisies
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
US8404637B2 (en) 2005-02-11 2013-03-26 Amylin Pharmaceuticals, Llc GIP analog and hybrid polypeptides with selectable properties
EP2392595A1 (fr) 2005-02-11 2011-12-07 Amylin Pharmaceuticals Inc. Analogues de GIP et polypeptides hybrides de GIP aux propriétés sélectionnables
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
EP2390264A1 (fr) 2005-02-11 2011-11-30 Amylin Pharmaceuticals Inc. Analogues de GIP et polypeptides hybrides de GIP aux propriétés sélectionnables
US8895498B2 (en) 2005-02-11 2014-11-25 Astrazeneca Pharmaceuticals, Lp GIP and exendin hybrid polypeptides
US9133260B2 (en) 2005-02-11 2015-09-15 Amylin Pharmaceuticals, Llc GIP analog and hybrid polypeptides with selectable properties
EP2330124A2 (fr) 2005-08-11 2011-06-08 Amylin Pharmaceuticals Inc. Polypeptides hybrides ayant des propriétés sélectionnables
EP2330125A2 (fr) 2005-08-11 2011-06-08 Amylin Pharmaceuticals, Inc. Polypeptides hybrides ayant des propriétés sélectionnables
US8497240B2 (en) 2006-08-17 2013-07-30 Amylin Pharmaceuticals, Llc DPP-IV resistant GIP hybrid polypeptides with selectable properties
WO2008056963A1 (fr) * 2006-11-10 2008-05-15 Chanil Moon Procédé permettant la prolifération de cellules souches au moyen de leptine

Also Published As

Publication number Publication date
AU5083098A (en) 1998-05-22

Similar Documents

Publication Publication Date Title
Hirayama et al. The flt3 ligand supports proliferation of lymphohematopoietic progenitors and early B-lymphoid progenitors
US5681559A (en) Method for producing a highly enriched population of hematopoietic stem cells
Strife et al. Activities of four purified growth factors on highly enriched human hematopoietic progenitor cells
US5821108A (en) Enrichment for a thymocyte subset having progenitor cell activity using c-kit as a selection marker
US5985660A (en) Method of identifying biological response modifiers involved in dendritic and/or lymphoid progenitor cell proliferation and/or differentiation
WO1998018486A1 (fr) Utilisation de la leptine pour stimuler l'hematopoiese
AU717783B2 (en) Methods for use of Mpl ligands with primitive human stem cells
US20020197717A1 (en) Human marrow stromal cell lines which sustain hematopoiesis
US20110143430A1 (en) Hematopoietic stem cell identification and isolation
WO1997021802A1 (fr) Nouvelles populations cellulaires embryonnaires et precedes permettant d'isoler lesdites populations
Rios et al. Systematic analysis of the ability of stromal cell lines derived from different murine adult tissues to support maintenance of hematopoietic stem cells in vitro
JP2010525836A (ja) ヒト造血幹細胞のｅｘｖｉｖｏ増殖
Schmitt et al. CD34-expressing human thymocyte precursors proliferate in response to interleukin-7 but have lost myeloid differentiation potential
Ratajczak et al. Recombinant human thrombopoietin (TPO) stimulates erythropoiesis by inhibiting erythroid progenitor cell apoptosis
Carlo-Stella et al. Identification of Philadelphia-negative granulocyte-macrophage colony-forming units generated by stroma-adherent cells from chronic myelogenous leukemia patients
US20040072259A1 (en) Methods and products for manipulating hematopoietic stem cells
Ishida et al. Expansion of natural killer cells but not T cells in human interleukin 2/interleukin 2 receptor (Tac) transgenic mice.
JPH06508528A (ja) インビトロ由来ヒト好中球前駆体細胞
JP2002502599A (ja) 増殖され遺伝子的に修飾されたヒト造血幹細胞集団
JP3957746B2 (ja) 骨髄始原細胞および／またはリンパ系始原細胞について富化される細胞集団、ならびに製造方法および使用方法
Pistoia et al. Large granular lymphocytes from patients with expanded LGL populations acquire cytotoxic functions and release lymphokines upon in vitro activation
KR20230013022A (ko) 골수성 악성종양의 치료를 위한 v 델타1+ t 세포
JP2022540267A (ja) Ｃｉｍｌ ｎｋ細胞及びそれについての方法
US20120201792A1 (en) Methods and products for manipulating hematopoietic stem cells
Ahmed et al. Gene transfer of alpha interferon into hematopoietic stem cells

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载